Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In-House IVD Manufacturers Get Extra Time To Comply With IVD Directive

This article was originally published in The Gray Sheet

Executive Summary

UK health institutions that manufacture in vitro diagnostics "in-house" and are subject to the IVD Directive will have until the end of 2005 to come into compliance with directive requirements

You may also be interested in...



In-House IVDs On Outside Samples Exempt From UK Regs – MHRA Guidance

UK health institutions that use in-house-prepared in vitro diagnostics remain exempt from IVD Directive requirements when samples come from a different legal entity, according to a recent MHRA guidance

In-House IVDs On Outside Samples Exempt From UK Regs – MHRA Guidance

UK health institutions that use in-house-prepared in vitro diagnostics remain exempt from IVD Directive requirements when samples come from a different legal entity, according to a recent MHRA guidance

International News In Brief

Hong Kong launches device regs: Department of Health releases 1public consultation paper July 4 on proposed regulatory framework addressing Hong Kong's lack of device premarket controls, formal adverse event reporting system and surveillance network. A new risk-benefit approach, in line with Global Harmonization Task Force principles, requires registration and personnel limits for higher-risk devices. DoH will hold three public forums in July on the consultation, which expires Sept. 30. An administrative control system proposal is scheduled for implementation next year...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018969

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel